22:39 , Jun 16, 2017 |  BC Extra  |  Clinical News

Merck team ties PD-L2 to immunotherapy response

In a paper published in...
07:00 , Sep 1, 2016 |  BC Innovations  |  Translation in Brief

Malaria's checkpoint sister

With all eyes on the interaction of PD-1 with its ligand PD-L1 in immuno-oncology, an Australian group has highlighted the therapeutic potential of a second ligand, PD-L2 , which could be exploited for driving immunity...
07:00 , May 29, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Asthma Programmed cell death 1 ligand 2 (PDCD1LG2; B7-DC; PD-L2); repulsive guidance molecule family member b (RGMB) In vitro and mouse studies suggest promoting the...
08:00 , Jan 13, 2014 |  BioCentury  |  Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer  An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
07:00 , Sep 9, 2013 |  BioCentury  |  Product Development

Checkpoint complementarity

The acquisition of Amplimmune Inc. adds a new set of immune checkpoint targets to MedImmune LLC 's cancer portfolio, giving it more potential combinations to test in cancer. The AstraZeneca plc unit now has four...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

Amplimmune, AstraZeneca deal

AstraZeneca's MedImmune LLC biologics unit will acquire cancer immunotherapy company Amplimmune for $225 million up front and up to $275 million in development milestones. MedImmune will gain Amplimmune's pipeline of immunomodulators, including Amplimmune's most advanced...
00:07 , Aug 27, 2013 |  BC Extra  |  Company News

MedImmune to acquire Amplimmune

The MedImmune LLC biologics unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) will acquire cancer immunotherapy company Amplimmune Inc. (Rockville, Md.) for $225 million up front and up to $275 million in milestones. MedImmune will gain Amplimmune's...
07:00 , Jun 18, 2012 |  BioCentury  |  Product Development

Immune springboard

A spate of Phase III data events over the next two years will give a readout on how correctly the lessons learned five years ago about cancer immunotherapies targeting T cell responses have been put...
07:00 , Aug 19, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Infectious disease Viral infection PD-1 receptor (PDCD1; PD-1; CD279); programmed cell death 1 ligand 1 (CD274 molecule; PD-L1; B7-H1); hepatitis A virus cellular receptor 2...
07:00 , Aug 9, 2010 |  BC Week In Review  |  Company News

Amplimmune, GlaxoSmithKline deal

Amplimmune granted GlaxoSmithKline an exclusive, worldwide license to develop and commercialize AMP-224 and other next-generation fusion proteins targeting PD-1 receptor ( PDCD1 ; PD-1; CD279 ). Amplimmune will receive $23 million up front and is...